Beate Kehrel

Prof. Dr. Beate Kehrel

University Hospital Muenster

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2005 in Seminars in Thrombosis and Hemostasis
Verified
Journal Article
Closed access
KJKerstin Jurk
Kerstin Jurk
BKBeate Kehrel
Beate Kehrel
Platelets are specialized blood cells that play central roles in physiologic and pathologic processes of hemostasis, inflammation, tumor metastasis, wound healing, and host defense. Activation of platelets is crucial for platelet function that includes a complex interplay of adhesion and signaling molecules. This article gives an overview of the activation processes involved in primary and secondary hemostasis, for example, platelet adhesion, platelet secretion, platelet aggregation, microvesicle formation, and clot retraction/stabilization. In addition, activated platelets are predominantly involved in cross talk to other blood and vascular cells. Stimulated “sticky” platelets enable recruitment of leukocytes at sites of vascular injury under high shear conditions. Platelet-derived microparticles as well as soluble adhesion molecules, sP-selectin and sCD40L, shed from the surface of activated platelets, are capable of activating, in turn, leukocytes and endothelial cells. This article focuses further on the new view of receptor-mediated thrombin generation of human platelets, necessary for the formation of a stable platelet-fibrin clot during secondary hemostasis. Finally, special emphasis is placed on important stimulatory and inhibitory signaling pathways that modulate platelet function.

15 September 2000
Verified
Journal Article
Closed access
JHJ Hartleib
J Hartleib
NKN Köhler
N Köhler
RDR B Dickinson
R B Dickinson
GCG S Chhatwal
G S Chhatwal
JSJ J Sixma
J J Sixma
MHM Herrmann
M Herrmann

19 September 2011 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
KJK. Jurk
K. Jurk
JLJ. Lahav
J. Lahav
HAH. VAN Aken
H. VAN Aken
MBM. F. Brodde
M. F. Brodde
JNJ.‐R. Nofer
J.‐R. Nofer
BKBeate Kehrel
Beate Kehrel

1 January 2004 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
KJKerstin Jurk
Kerstin Jurk
UJUli-Rüdiger Jahn
Uli-Rüdiger Jahn
HAHugo Van Aken
Hugo Van Aken
CSCarsten Schriek
Carsten Schriek
DDDirk W. Droste
Dirk W. Droste
BKBeate Kehrel
Beate Kehrel
Platelet activation is involved in the pathogenesis of cerebrovascular ischemia, but the major agonist involved has yet to be identified. To investigate the role of thrombin in platelet activation in patients with acute ischemic stroke, and while thrombin is the most likely candidate for activation of the thrombin receptor PAR-1 in vivo, we assessed its cleavage and internalization using the antibodies SPAN12, binding to uncleaved PAR-1, and WEDE15, recognizing cleaved and uncleaved, but not internalized PAR-1. In contrast to healthy age-matched controls, platelets from stroke patients exhibited significant cleavage and internalization of PAR-1 (P<0.001) and failed to respond to thrombin in vitro. Enhanced surface expression of CD62P, CD63, TSP-1 and less mepacrine uptake showed platelet degranulation during stroke. Platelets from patients with acute cerebral ischemia are exhausted and desensitized to thrombin through cleavage of PAR-1, indicating that high concentrations of thrombin occur with acute cerebrovascular ischemic events in vivo.

18 March 2013 in Transfusion Medicine and Hemotherapy
Verified
Journal Article
Closed access
PDF file
BKBeate Kehrel
Beate Kehrel
MBMartin F. Brodde
Martin F. Brodde
Platelets perform many functions in hemostasis but also in other areas of physiology and pathology. Therefore, it is obvious that many different function tests have been developed, each one conceived and standardized for a special purpose. This review will summarize the different fields in which platelet function testing is currently in use; diagnostics of patients with bleeding disorders, monitoring patients' response to anti-platelet therapy, monitoring in transfusion medicine (blood donors, platelet concentrates, and after transfusion), and monitoring in perioperative medicine to predict bleeding tendency. The second part of the review outlines different methods for platelet function testing, spanning bleeding time, and platelet counting as well as determining platelet adhesion, platelet secretion, platelet aggregation, platelet morphology, platelet signal transduction, platelet procoagulant activity, platelet apoptosis, platelet proteomics, and molecular biology.

1 February 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SNSilke Niemann
Silke Niemann
ABAnne Bertling
Anne Bertling
MBMartin F. Brodde
Martin F. Brodde
AFAnke C. Fender
Anke C. Fender
HVHélène Van de Vyver
Hélène Van de Vyver
BKBeate Kehrel
Beate Kehrel
Globalization and migration promote the spread of Panton-Valentine leukocidin (PVL)-positive Staphylococcus aureus strains. The toxin PVL is linked to the development of thrombosis in association with osteomyelitis. The mechanisms by which PVL drives thrombosis development are however still unknown. We demonstrate that PVL-damaged neutrophils activate platelets via neutrophil secretion products, such as α-defensins and the myeloperoxidase product HOCl, as well as the formation of HOCl-modified proteins. Neutrophil damage by PVL is blocked by anti-PVL-antibodies, explaining why especially young osteomyelitis patients with a low antibody titre against PVL suffer from thrombotic complications. Platelet activation in the presence of PVL-damaged neutrophils is prevented by α-defensin inhibitors and by glutathione and resveratrol, which are both inhibitors of HOCl-modified protein-induced platelet activation. Remarkably, intravenously infused glutathione also prevents activation of human platelets in an ex vivo assay. We here describe a new mechanism of PVL-neutrophil-platelet interactions, which might be extrapolated to other toxins that act on neutrophils. Our observations may make us think about new approaches to treat and/or prevent thrombotic complications in the course of infections with PVL-producing S. aureus strains.